Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Seeking Alpha8/13/2026Neutral
TLPH
Talphera Inc.NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$62.29M
P/E Ratio
—
EPS
$-0.23
Beta
0.70
52W High
$1.57
52W Low
$0.42
50-Day MA
$1.18
200-Day MA
$1.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
1.02
PEG Ratio
—
About Talphera Inc.
Talphera Inc. is a pioneering biotechnology company dedicated to advancing peptide-based therapies for rare diseases and significant unmet medical needs. Its promising pipeline, especially in developing innovative cancer treatments, highlights the firm's potential for substantial growth within the biopharmaceutical industry. Committed to rigorous research and focused on delivering transformative health solutions, Talphera represents a compelling investment opportunity for institutional investors seeking to capitalize on the dynamic biotech landscape.
Fundamentals
| Revenue (TTM) | 1,000 |
| Gross Profit (TTM) | -245,000 |
| EBITDA | $-15.16M |
| Operating Margin | -1474700.00% |
| Return on Equity | -118.40% |
| Return on Assets | -40.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.37 |
| Price-to-Book | 4.39 |
| Price-to-Sales (TTM) | 62286.96 |
| EV/Revenue | 46241.57 |
| EV/EBITDA | 0.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $51.91M |
| Float | $25.87M |
| % Insiders | 21.41% |
| % Institutions | 45.96% |
Historical Volatility
HV 10-Day
90.54%
HV 20-Day
78.13%
HV 30-Day
76.67%
HV 60-Day
74.36%
HV Rank
45.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($3.17 target)
1
Strong Buy2
BuyLatest News
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced financial results for the second quarter of 2026 and provided a corporate update on the development of nafamostat.
PRNewsWire8/12/2026Neutral
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.
PRNewsWire8/5/2026Neutral
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.
PRNewsWire5/13/2026Neutral
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m.
PRNewsWire5/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TLPH and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026